Slide 1: Q2 2025 Earnings Call
Q2 2025 EARNINGS CALL OFER HAVIV | PRESIDENT & CEO August 19, 2025
Slide 2: Forward-looking statements
This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are co
Slide 3: Agenda
Earnings Call Q2 2025 AGENDA Q&A 3 CEO Update - By Ofer Haviv CFO Update - By Yaron Eldad
Slide 4: CEO Update: Financial Highlights
4 4 CEO UPDATE Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a subsidiary of Evogene and the MicroBoost AI for Ag operations, are presented as a single-line item in Evogene’s consolidated P&L statements for the first half of 2025. Their results are included und
Slide 5: CEO Update: Financial Highlights
5 5 CEO UPDATE Financial Highlights: Total research and development expenses in the first half of 2025 were approximately $4.8 million, compared to approximately $6.5 million in the first half of 2024. The decrease is primarily attributable to a reduction in Biomica’s R&D activities and the disconti
Slide 6: CEO Update: New Strategic Focus
6 6 CEO UPDATE New Strategic Focus Enhancing ChemPass AI’s value proposition in the field of AI powered small molecule discovery and optimization and expanding its utilization for the pharmaceutical and agriculture industries. 2025 Strategic Priorities Strengthening ChemPass AI as a core asset Expan
Slide 7: Q2 2025 to date, Strategy Implementation
7 7 CEO UPDATE Q2 2025 to date, Strategy Implementation ChemPass AI: Launch of Generative AI Foundational Model Strategic Research Collaboration with Tel Aviv University - Develop small molecule therapeutics targeting diseases caused by metabolite accumulation Integrating AgPlenus activities into Ev
Slide 8: Strategy Implementation – Cont.
8 8 CEO UPDATE Q2 2025 to date, Strategy Implementation – Cont. Streamlining Operations Expenses - Biomica - Workforce reduction and management change - Evogene – Restructuring & workforce reduction ~30% Financial Strengthening June 2025 - $4.4 million raised through a public share offering based on
Slide 9: Looking Ahead
Looking Ahead Evogene ChemPass AI - Keep our competitive edge , elevate our platform’s performance and precision. Pharma - Establish a partner ecosystem in pharma across academia and industry, in Israel and internationally. Agriculture (AgPlenus) - Further growth, including new partnerships with bot
Slide 10: Agenda
Earnings Call Q2 2025 AGENDA Q&A 10 CEO Update - By Ofer Haviv CFO Update - By Yaron Eldad
Slide 11: Consolidated Interim Statements of Financial Position
H CFO UPDATE |CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION U.S. dollars in thousands ASSETS ‘CURRENT ASSETS: Cash and cash equivalents Short-term bank deposits Trade receivables Other receivables and prepaid expenses Deferred expenses related to issuance of warrants Assets held for sale Inv
Slide 12: Consolidated Interim Statements of Financial Position (Liabilities and Equity)
H CFO UPDATE CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION ., US. dollars in thousands June 30, December 31, 2025, "004 Taauaited LIABILITIES AND EQUITY (CURRENT LIABILITIES: ‘Trade payables, s 387 s 1228 Employees and payroll accruals 173 1869 Lease liabilities ‘ss0 589 Liabilities in respe
Slide 13: Evogene Financial Performance Q2 2025
CFO UPDATE Evogene Financial Performance Q2 2025 13
Slide 14: Agenda
Earnings Call Q2 2025 AGENDA Q&A 14 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 15: Thank You
THANK YOU